A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
|Articles|November 10, 2021
Daily Medication Pearl: Durvalumab (Imfinzi) for Non-Small Cell Lung Cancer
Author(s)Saro Arakelians, PharmD
Listen
0:00 / 0:00
Key Takeaways
- Durvalumab is indicated for unresectable, stage III NSCLC, administered biweekly or monthly via injection.
- Common adverse events include cough, fatigue, pneumonitis, and upper respiratory tract infections.
Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80.
Advertisement
Medication Pearl of the Day: Durvalumab (Imfinzi)
Indication: Imfinzi is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with unresectable, stage III non-small cell lung cancer (NSCLC).
Insight:
- Dosing: 10 mg/kg every 2 weeks or 1500 mg every 4 weeks.
- Dosage form: Injection 500 mg/10 mL (50 mg/mL) solution in a single-dose vial. Injection 120 mg/2.4 mL (50 mg/mL) solution in a single-dose vial.
- Adverse events (AEs): Most common AEs were cough, fatigue, pneumonitis/radiation pneumonitis, upper respiratory tract infections, dyspnea, and rash.
- Mechanism of action: Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 (B7.1). Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, without inducing antibody dependent cell-mediated cytotoxicity.
- Manufacturer: AstraZeneca
Sources:
Advertisement
Related to this article
Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.
Phase 3 HARMONi-2 interim analysis shows first bispecific PD-1/VEGF antibody outperforming standard immunotherapy in first-line NSCLC.
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
The FDA expanded the accelerated approval of sevabertinib to include treatment-naive adults with locally advanced or metastatic nonsquamous NSCLC harboring HER2 tyrosine kinase domain-activating mutations.
The phase 3 DeLLphi-305 trial found that the first-line maintenance therapy improved overall survival in extensive-stage small cell lung cancer (ES-SCLC) compared with durvalumab alone.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systems
2
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
3
Pharmacists' Role as Ketone Monitoring Reaches Clinics
4
Bladder Cancer Treatment Is Advancing Faster Than Answers on Sequencing and Toxicity Management
5